Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,960
+200 (1.19%)
Apr 10, 2026, 3:30 PM KST
Market Cap406.71B -9.0%
Revenue (ttm)3.76B +59.2%
Net Income-8.99B
EPS-374.00
Shares Out24.27M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume71,061
Average Volume111,158
Open16,950
Previous Close16,760
Day's Range16,610 - 17,000
52-Week Range11,390 - 33,300
Beta0.24
RSI39.31
Earnings DateApr 2, 2026

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2025, Genomictree's revenue was 3.76 billion, an increase of 59.17% compared to the previous year's 2.36 billion. Losses were -8.99 billion, -12.27% less than in 2024.

Financial Statements